Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of blood analysis specialist Abaxis
So what: These first-quarter results were not what the doctor ordered. The company's 3% sales growth year over year produced 37% lower earnings, as rising operating costs cut into margins. Analysts had expected flat earnings and 10% higher revenue.
Now what: Abaxis normally boasts a much fatter operating margin than rivals Alere
But riddle me this, dear investor: Why would an investor in the medical sector take a chance on Abaxis turning these issues around, rather than banking on the proven growth of Intuitive Surgical
Interested in more info on Abaxis? Add it to your watchlist.